Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Huiyan Zeng Author

hzeng@bidmc.harvard.edu 617-667-2329 | 617-667-2329

Subjects of specialization
Mucoepidermoid carcinoma, Cancer chemotherapy, Prostate biomarker, Rickets

Affiliation
Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA

Biography

Huiyan Zeng was working in the Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. and also in the  Department of Medicine, Hematology and Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.

Publications

Research Article Open Access

Orphan Nuclear Receptor TR3/Nur77 is a Specific Therapeutic Target for Hepatic Cancers

Author(s):

Yingling Zeng, Xiaoguang Ye, Degui Liao, Shizhang Huang, Huinan Mao, Dezheng Zhao and Huiyan Zeng

Objective: Although great success has been achieved in cancer treatment, current cancer therapies, including anti-tumorigenesis and anti-angiogenesis, still face the problems of insufficient efficacy, resistance and intrinsic refractoriness, in addition to their toxic side effects. There is a demand to identify additional targets that can be blocked to turn off the downstream effects of most, if not all, pathways. Our previous studies suggest that orphan nuclear receptor TR3 (human) / Nur77 (mouse) is such a target. However, the correlation of TR3 expression and clinical tumor progression has not been studied.

Methods: The expression of TR3 was analysed in human primary hepatic cancer spe... view more»

DOI: 10.4172/2324-9110.1000184

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP